Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: A retrospective study has shown that EGFr (epidermal growth factor–like repeat) group in the NOTCH3 gene is an important cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease modifier of age at first stroke and white matter hyperintensity (WMH) volume. No study has yet assessed the effect of other known CADASIL modifiers, that is, cardiovascular risk factors and sex, in the context of NOTCH3 EGFr group. In this study, we determined the relative disease-modifying effects of NOTCH3 EGFr group, sex and cardiovascular risk factor on disease severity in the first genotype-driven, large prospective CADASIL cohort study, using a comprehensive battery of CADASIL clinical outcomes and neuroimaging markers. Methods: Patients with CADASIL participated in a single-center, prospective cohort study (DiViNAS [Disease Variability in NOTCH3 Associated Small Vessel Disease]) between 2017 and 2020. The study protocol included a clinical assessment, neuropsychological test battery and brain magnetic resonance imaging on a single research day. Multivariable linear, logistic and Cox regression models were used to cross-sectionally assess the effect of CADASIL modifiers on clinical severity (stroke, disability, processing speed) and neuroimaging markers (WMH volume, peak width of skeletonized mean diffusivity, lacune volume, brain volume, cerebral microbleed count). Results: Two hundred patients with CADASIL participated, of which 103 harbored a NOTCH3 EGFr 1–6 variant and 97 an EGFr 7–34 variant. NOTCH3 EGFr 1–6 group was the most important modifier of age at first stroke (hazard ratio, 2.45 [95% CI, 1.39–4.31]; P =0.002), lacune volume (odds ratio, 4.31 [95% CI, 2.31–8.04]; P =4.0×10 -6 ), WMH volume (B=0.81 [95% CI, 0.60–1.02]; P =1.1×10 -12 ), and peak width of skeletonized mean diffusivity (B=0.65 [95% CI, 0.44–0.87]; P =1.6×10 -8 ). EGFr 1–6 patients had a significantly higher WMH volume in the anterior temporal lobes and superior frontal gyri and a higher burden of enlarged perivascular spaces. After NOTCH3 EGFr group, male sex and hypertension were the next most important modifiers of clinical outcomes and neuroimaging markers. Conclusions: NOTCH3 EGFr group is the most important CADASIL disease modifier not only for age at first stroke and WMH volume but also strikingly so for a whole battery of clinically relevant disease measures such as lacune volume and peak width of skeletonized mean diffusivity. NOTCH3 EGFr group is followed in importance by sex, hypertension, diabetes, and smoking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chabriat, H., Joutel, A., Dichgans, M., Tournier-Lasserve, E., & Bousser, M.-G. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70127-9 · Cited by 1,088
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients
Joutel, A., Vahedi, K., Corpechot, C., Troesch, A., Chabriat, H., Vayssière, C., Cruaud, C., Maciazek, J., Weissenbach, J., Bousser, M.-G., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08083-5 · Cited by 682
Baykara, E., Gesierich, B., Adam, R., Tuladhar, A. M., Biesbroek, J. M., Koek, H. L., Ropele, S., Jouvent, E., Initiative, A. D. N., Chabriat, H., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24758 · Cited by 386
Adib-Samii, P., Brice, G., Martin, R. J., & Markus, H. S. (2010) · Stroke · doi:10.1161/strokeaha.109.568402 · Cited by 239
Viswanathan, A. (2006) · Brain · doi:10.1093/brain/awl177 · Cited by 205
Duering, M., Zieren, N., Hervé, D., Jouvent, E., Reyes, S., Peters, N., Pachai, C., Opherk, C., Chabriat, H., & Dichgans, M. (2011) · Brain · doi:10.1093/brain/awr169 · Cited by 200
Rutten, J. W., Van Eijsden, B. J., Duering, M., Jouvent, E., Opherk, C., Pantoni, L., Federico, A., Dichgans, M., Markus, H. S., Chabriat, H., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0088-3 · Cited by 169
Self-citationHoltmannspötter, M., Peters, N., Opherk, C., Martin, D., Herzog, J., Brückmann, H., Sämann, P., Gschwendtner, A., & Dichgans, M. (2005) · Stroke · doi:10.1161/01.str.0000189696.70989.a4 · Cited by 140
Brain volume changes in CADASIL: A serial MRI study in pure subcortical ischemic vascular disease
Peters, N., Holtmannspötter, M., Opherk, C., Gschwendtner, A., Herzog, J., Sämann, P., & Dichgans, M. (2006) · Neurology · doi:10.1212/01.wnl.0000216271.96364.50 · Cited by 130
Dilated perivascular spaces in small-vessel disease: a study in CADASIL
Yao, M., Hervé, D., Jouvent, E., Duering, M., Reyes, S., Godin, O., Guichard, J. P., Dichgans, M., & Chabriat, H. (2014) · Cerebrovascular Diseases · doi:10.1159/000356982 · Cited by 71
Zieren, N., Duering, M., Peters, N., Reyes, S., Jouvent, E., Hervé, D., Gschwendtner, A., Mewald, Y., Opherk, C., Chabriat, H., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.019 · Cited by 65
Cited by
Hack, R. J., Gravesteijn, G., Cerfontaine, M. N., Santcroos, M. A., Gatti, L., Kopczak, A., Bersano, A., Duering, M., Rutten, J. W., & Lesnik Oberstein, S. A. J. (2023) · Brain · doi:10.1093/brain/awac486 · Cited by 60
“Further details including statistically significant differences in the burden of SVD imaging markers and risk of stroke between EGFr domains are shown in Supplementary Tables 5 and 6. involved in ligand binding.”
Self-citationMeschia, J. F., Worrall, B. B., Elahi, F. M., Ross, O. A., Wang, M. M., Goldstein, E. D., Rost, N. S., Majersik, J. J., Gutierrez, J., & on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Hypertension (2023) · Stroke · doi:10.1161/str.0000000000000444 · Cited by 44
Disease Severity Staging System for NOTCH3 -Associated Small Vessel Disease, Including CADASIL
Gravesteijn, G., Rutten, J. W., Cerfontaine, M. N., Hack, R. J., Liao, Y.-C., Jolly, A. A., Guey, S., Hsu, S.-L., Park, J.-Y., Yuan, Y., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2024.4487 · Cited by 25
Self-citation
Metadata
- Authors
- Hack, R. J., Cerfontaine, M. N., Gravesteijn, G., Tap, S., Hafkemeijer, A., van der Grond, J., Witjes-Ané, M.-N., Baas, F., Rutten, J. W., & Lesnik Oberstein, S. A. J.
- Venue
- Stroke
- Published
- 2022-10
- Volume
- 53
- Issue
- 10
- Pages
- 3133-3144
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W4285086889
- Cited by
- 42
- References
- 11
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.